Tedizolid PO — Competitive Intelligence Brief

Tedizolid PO (Tedizolid PO) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oxazolidinone antibiotic. Area: Infectious Disease.

marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Tedizolid PO (Tedizolid PO) — University of Southern California. Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tedizolid PO TARGET	Tedizolid PO	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 1gm	Azithromycin 1gm	Ain Shams Maternity Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
CLDM 1% gel	CLDM 1% gel	GlaxoSmithKline	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
AzaSite®	AzaSite®	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithropycin according to symptoms	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Azithromycin 3 days	Azithromycin 3 days	University of Oxford	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oxazolidinone antibiotic class)

1. Fundacion Clinic per a la Recerca Biomédica · 2 drugs in this class
2. University of Southern California · 2 drugs in this class
3. Arpida AG · 2 drugs in this class
4. Pfizer · 1 drug in this class
5. Shenzhen Third People's Hospital · 1 drug in this class
6. Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
7. Wuhan Pulmonary Hospital · 1 drug in this class
8. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class